Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Imeglimin Formulations in Healthy Volunteers
NCT03646331Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Sep 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Poxel SA. Primary endpoint: Pharmacokinetic parameters of imeglimin at 48 hours. Started Sep 2018; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03646331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646331.